Coexpression analysis of CD133 and CD44 identifies Proneural and Mesenchymal subtypes of glioblastoma multiforme

Oncotarget

Volumn 6, Issue 8, 2015, Pages 6267-6280

  Brown, Daniel V ^a   Daniel, Paul M ^a   D'Abaco, Giovanna M ^a   Gogos, Andrew ^a   Ng, Wayne ^a   Morokoff, Andrew P ^a   Mantamadiotis, Theo ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Cancer genome atlas; Cancer stem cells; Coexpression; Glioblastoma; Molecular subtype

Indexed keywords

CD133 ANTIGEN; DNA; HERMES ANTIGEN; MESSENGER RNA; TEMOZOLOMIDE; DACARBAZINE; GLYCOPROTEIN; LEUKOCYTE ANTIGEN; PEPTIDE; PROM1 PROTEIN, HUMAN; TUMOR MARKER;

ANTIGEN EXPRESSION; ARTICLE; CANCER CLASSIFICATION; CANCER PATIENT; CANCER STEM CELL; CARCINOGENESIS; CELL CYCLE; CELL GROWTH; CELL MIGRATION; CONTROLLED STUDY; DNA REPLICATION; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; GENETIC ANALYSIS; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; LONG TERM SURVIVAL; MESENCHYMAL STEM CELL; NEURAL STEM CELL; PHENOTYPE; RADIATION RESPONSE; TREATMENT RESPONSE; TUMOR INVASION; ANALOGS AND DERIVATIVES; BIOSYNTHESIS; BRAIN NEOPLASMS; CELL PROLIFERATION; CLASSIFICATION; GENE EXPRESSION PROFILING; GENETICS; MESODERM; METABOLISM; PATHOLOGY; PHYSIOLOGY; PREDICTIVE VALUE;

AC133 ANTIGEN; ANTIGENS, CD; ANTIGENS, CD44; BIOMARKERS, TUMOR; BRAIN NEOPLASMS; CELL PROLIFERATION; DACARBAZINE; GENE EXPRESSION PROFILING; GLIOBLASTOMA; GLYCOPROTEINS; HUMANS; MESODERM; NEOPLASTIC STEM CELLS; NEURAL STEM CELLS; PEPTIDES; PREDICTIVE VALUE OF TESTS;

EID: 84925612958     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3365     Document Type: Article

References (63)

1. Miller CR and Perry A. Glioblastoma: morphologic and molecular genetic diversity. Archives of pathology & laboratory medicine. 2007; 131(3):397-406.
2. Smoll NR, Schaller K and Gautschi OP. Long-term survival of patients with glioblastoma multiforme (GBM). Journal of clinical neuroscience: official journal of the Neurosurgical Society of Australasia. 2013; 20(5):670-675.
3. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, Misra A, Nigro JM, Colman H, Soroceanu L, Williams PM, Modrusan Z, Feuerstein BG and Aldape K. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell. 2006; 9(3):157-173.
4. Verhaak RGW, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O'Kelly M, Tamayo P, Weir BA, Gabriel S, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010; 17(1):98-110.
5. Brennan CW, Verhaak RGW, McKenna A, Campos B, Noushmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ, Berman SH, Beroukhim R, Bernard B, Wu C-J, Genovese G, Shmulevich I, Barnholtz-Sloan J, et al. The somatic genomic landscape of glioblastoma. Cell. 2013; 155(2):462-477.
6. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. The New England journal of medicine. 2005; 352(10):987-996.
7. Field KM, Drummond KJ, Yilmaz M, Tacey M, Compston D, Gibbs P and Rosenthal MA. Clinical trial participation and outcome for patients with glioblastoma: multivariate analysis from a comprehensive dataset. Journal of clinical neuroscience: official journal of the Neurosurgical Society of Australasia. 2013; 20(6):783-789.
8. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J and Dirks PB. Identification of a cancer stem cell in human brain tumors. Cancer Research. 2003; 63(18):5821-5828.
9. Johnson KW, Dooner M and Quesenberry PJ. Fluorescence activated cell sorting: a window on the stem cell. Current pharmaceutical biotechnology. 2007; 8(3):133-139.
10. Greve B, Kelsch R, Spaniol K, Eich HT and Götte M. Flow cytometry in cancer stem cell analysis and separation. Cytometry Part A: the journal of the International Society for Analytical Cytology. 2012; 81(4):284-293.
11. Marzesco A-M, Janich P, Wilsch-Bräuninger M, Dubreuil V, Langenfeld K, Corbeil D and Huttner WB. Release of extracellular membrane particles carrying the stem cell marker prominin-1 (CD133) from neural progenitors and other epithelial cells. Journal of cell science. 2005; 118(Pt 13):2849-2858.
12. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD and Dirks PB. Identification of human brain tumour initiating cells. Nature. 2004; 432(7015):396-401.
13. Metellus P, Nanni-Metellus I, Delfino C, Colin C, Tchogandjian A, Coulibaly B, Fina F, Loundou A, Barrie M, Chinot O, Ouafik LH and Figarella-Branger D. Prognostic impact of CD133 mRNA expression in 48 glioblastoma patients treated with concomitant radiochemotherapy: a prospective patient cohort at a single institution. Annals of surgical oncology. 2011; 18(10):2937-2945.
14. Shibahara I, Sonoda Y, Saito R, Kanamori M, Yamashita Y, Kumabe T, Watanabe M, Suzuki H, Watanabe T, Ishioka C and Tominaga T. The expression status of CD133 is associated with the pattern and timing of primary glioblastoma recurrence. Neuro-oncology. 2013.
15. Shin JH, Lee YS, Hong Y-K and Kang CS. Correlation between the prognostic value and the expression of the stem cell marker CD133 and isocitrate dehydrogenase1 in glioblastomas. Journal of neuro-oncology. 2013.
16. Kim K-J, Lee K-H, Kim H-S, Moon K-S, Jung T-Y, Jung S and Lee M-C. The presence of stem cell marker-expressing cells is not prognostically significant in glioblastomas. Neuropathology: official journal of the Japanese Society of Neuropathology. 2011; 31(5):494-502.
17. Fouse SD, Nakamura JL, James CD, Chang S and Costello JF. Response of primary glioblastoma cells to therapy is patient specific and independent of cancer stem cell phenotype. Neuro-oncology. 2013.
18. Stieber D, Golebiewska A, Evers L, Lenkiewicz E, Brons NHC, Nicot N, Oudin A, Bougnaud S, Hertel F, Bjerkvig R, Vallar L, Barrett MT and Niclou SP. Glioblastomas are composed of genetically divergent clones with distinct tumourigenic potential and variable stem cell-associated phenotypes. Acta neuropathologica. 2013.
19. Liu Y, Han SSW, Wu Y, Tuohy TMF, Xue H, Cai J, Back SA, Sherman LS, Fischer I and Rao MS. CD44 expression identifies astrocyte-restricted precursor cells. Developmental biology. 2004; 276(1):31-46.
20. Son MJ, Woolard K, Nam D-H, Lee J and Fine HA. SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma. Cell stem cell. 2009; 4(5):440-452.
21. Bao S, Wu Q, Li Z, Sathornsumetee S, Wang H, McLendon RE, Hjelmeland AB and Rich JN. Targeting cancer stem cells through L1CAM suppresses glioma growth. Cancer Research. 2008; 68(15):6043-6048.
22. Lathia JD, Gallagher J, Heddleston JM, Wang J, Eyler CE, MacSwords J, Wu Q, Vasanji A, McLendon RE, Hjelmeland AB and Rich JN. Integrin alpha 6 regulates glioblastoma stem cells. Cell stem cell. 2010; 6(5):421-432.
23. Lottaz C, Beier D, Meyer K, Kumar P, Hermann A, Schwarz J, Junker M, Oefner PJ, Bogdahn U, Wischhusen J, Spang R, Storch A and Beier CP. Transcriptional profiles of CD133+ and CD133-glioblastoma-derived cancer stem cell lines suggest different cells of origin. Cancer Research. 2010; 70(5):2030-2040.
24. Hägerstrand D, He X, Bradic Lindh M, Hoefs S, Hesselager G, Ostman A and Nistér M. Identification of a SOX2-dependent subset of tumor-and sphere-forming glioblastoma cells with a distinct tyrosine kinase inhibitor sensitivity profile. Neuro-oncology. 2011; 13(11):1178-1191.
25. Mao P, Joshi K, Li J, Kim S-H, Li P, Santana-Santos L, Luthra S, Chandran UR, Benos PV, Smith L, Wang M, Hu B, Cheng S-Y, Sobol RW and Nakano I. Mesenchymal glioma stem cells are maintained by activated glycolytic metabolism involving aldehyde dehydrogenase 1A3. PNAS. 2013; 110(21):8644-8649.
26. Bhat KPL, Balasubramaniyan V, Vaillant B, Ezhilarasan R, Hummelink K, Hollingsworth F, Wani K, Heathcock L, James JD, Goodman LD, Conroy S, Long L, Lelic N, Wang S, Gumin J, Raj D, et al. Mesenchymal differentiation mediated by NF-κB promotes radiation resistance in glioblastoma. Cancer Cell. 2013; 24(3):331-346.
27. Dong H, Luo L, Hong S, Siu H, Xiao Y, Jin L, Chen R and Xiong M. Integrated analysis of mutations, miRNA and mRNA expression in glioblastoma. BMC systems biology. 2010; 4:163.
28. Sun Y, Zhang W, Chen D, Lv Y, Zheng J, Lilljebjörn H, Ran L, Bao Z, Soneson C, Sjögren HO, Salford LG, Ji J, French PJ, Fioretos T, Jiang T and Fan X. A glioma classification scheme based on coexpression modules of EGFR and PDGFRA. PNAS. 2014; 111(9):3538-3543.
29. Yang Y, Han L, Yuan Y, Li J, Hei N and Liang H. Gene co-expression network analysis reveals common system-level properties of prognostic genes across cancer types. Nature Communications. 2014; 5:3231.
30. Gunther HS, Schmidt NO, Phillips HS, Kemming D, Kharbanda S, Soriano R, Modrusan Z, Meissner H, Westphal M and Lamszus K. Glioblastoma-derived stem cell-enriched cultures form distinct subgroups according to molecular and phenotypic criteria. Oncogene. 2008; 27(20):2897-2909.
31. Shats I, Gatza ML, Chang JT, Mori S, Wang J, Rich J and Nevins JR. Using a stem cell-based signature to guide therapeutic selection in cancer. Cancer Research. 2011; 71(5):1772-1780.
32. Aruffo A, Stamenkovic I, Melnick M, Underhill CB and Seed B. CD44 is the principal cell surface receptor for hyaluronate. Cell. 1990; 61(7):1303-1313.
33. Rath BH, Fair JM, Jamal M, Camphausen K and Tofilon PJ. Astrocytes enhance the invasion potential of glioblastoma stem-like cells. PLoS ONE. 2013; 8(1):e54752.
34. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES and Mesirov JP. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proceedings of the National Academy of Sciences of the United States of America. 2005; 102(43):15545-15550.
35. Rampazzo E, Persano L, Pistollato F, Moro E, Frasson C, Porazzi P, Della Puppa A, Bresolin S, Battilana G, Indraccolo S, Te Kronnie G, Argenton F, Tiso N and Basso G. Wnt activation promotes neuronal differentiation of Glioblastoma. Cell Death and Disease. 2013; 4(4):e597-591.
36. Takezaki T, Hide T, Takanaga H, Nakamura H, Kuratsu J-I and Kondo T. Essential role of the Hedgehog signaling pathway in human glioma-initiating cells. Cancer science. 2011; 102(7):1306-1312.
37. Rasper M, Schäfer A, Piontek G, Teufel J, Brockhoff G, Ringel F, Heindl S, Zimmer C and Schlegel J. Aldehyde dehydrogenase 1 positive glioblastoma cells show brain tumor stem cell capacity. Neuro-oncology. 2010; 12(10):1024-1033.
38. Cheng W-Y, Kandel JJ, Yamashiro DJ, Canoll P and Anastassiou D. A multi-cancer mesenchymal transition gene expression signature is associated with prolonged time to recurrence in glioblastoma. PLoS ONE. 2012; 7(4):e34705.
39. Yan X, Maa L, Yia D, Yoonb J-G, Diercksa A, Gregory Foltza B, Pricec ND, Hooda LE and Tian Q. A CD133-related gene expression signature identifies an aggressive glioblastoma subtype with excessive mutations. PNAS. 2011:1-13.
40. Holmberg Olausson K, Maire CL, Haidar S, Ling J, Learner E, Nistér M and Ligon KL. Prominin-1 (CD133) Defines Both Stem and Non-Stem Cell Populations in CNS Development and Gliomas. PLoS ONE. 2014; 9(9):e106694.
41. Hänzelmann S, Castelo R and Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC bioinformatics. 2013; 14:7.
42. Zhang B, Wang J, Wang X, Zhu J, Liu Q, Shi Z, Chambers MC, Zimmerman LJ, Shaddox KF, Kim S, Davies SR, Wang S, Wang P, Kinsinger CR, Rivers RC, Rodriguez H, et al. Proteogenomic characterization of human colon and rectal cancer. Nature. 2014.
43. Hermansen SK, Christensen KG, Jensen SS and Kristensen BW. Inconsistent immunohistochemical expression patterns of four different CD133 antibody clones in glioblastoma. Journal of Histochemistry and Cytochemistry. 2011; 59(4):391-407.
44. Jaksch M, Múnera J, Bajpai R, Terskikh A and Oshima RG. Cell cycle-dependent variation of a CD133 epitope in human embryonic stem cell, colon cancer, and melanoma cell lines. Cancer Research. 2008; 68(19):7882-7886.
45. Ruiz P, Schwärzler C and Günthert U. CD44 isoforms during differentiation and development. BioEssays: news and reviews in molecular, cellular and developmental biology. 1995; 17(1):17-24.
46. Thorne RF, Legg JW and Isacke CM. The role of the CD44 transmembrane and cytoplasmic domains in co-ordinating adhesive and signalling events. Journal of cell science. 2004; 117(Pt 3):373-380.
47. Günthert U, Hofmann M, Rudy W, Reber S, Zöller M, Haussmann I, Matzku S, Wenzel A, Ponta H and Herrlich P. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell. 1991; 65(1):13-24.
48. Jijiwa M, Demir H, Gupta S, Leung C, Joshi K, Orozco N, Huang T, Yildiz VO, Shibahara I, de Jesus JA, Yong WH, Mischel PS, Fernandez S, Kornblum HI and Nakano I. CD44v6 regulates growth of brain tumor stem cells partially through the AKT-mediated pathway. PLoS ONE. 2011; 6(9):e24217.
49. Pal S, Bi Y, Macyszyn L, Showe LC, O'Rourke DM and Davuluri RV. Isoform-level gene signature improves prognostic stratification and accurately classifies glioblastoma subtypes. Nucleic Acids Research. 2014.
50. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, Pan F, Pelloski CE, Sulman EP, Bhat KP, Verhaak RGW, Hoadley KA, Hayes DN, Perou CM, Schmidt HK, Ding L, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. 2010; 17(5):510-522.
51. Sottoriva A, Spiteri I, Piccirillo SGM, Touloumis A, Collins VP, Marioni JC, Curtis C, Watts C and Tavaré S. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. PNAS. 2013.
52. Patel AP, Tirosh I, Trombetta JJ, Shalek AK, Gillespie SM, Wakimoto H, Cahill DP, Nahed BV, Curry WT, Martuza RL, Louis DN, Rozenblatt-Rosen O, Suvà ML, Regev A and Bernstein BE. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science. 2014; 344(6190):1396-1401.
53. Ozawa T, Riester M, Cheng Y-K, Huse JT, Squatrito M, Helmy K, Charles N, Michor F and Holland EC. Most Human Non-GCIMP Glioblastoma Subtypes Evolve from a Common Proneural-like Precursor Glioma. Cancer Cell. 2014; 26(2):288-300.
54. Cline MS, Craft B, Swatloski T, Goldman M, Ma S, Haussler D and Zhu J. Exploring TCGA Pan-Cancer data at the UCSC Cancer Genomics Browser. Scientific reports. 2013; 3:2652.
55. Madhavan S, Zenklusen JC, Kotliarov Y, Sahni H, Fine HA and Buetow K. Rembrandt: helping personalized medicine become a reality through integrative translational research. Molecular cancer research: MCR. 2009; 7(2):157-167.
56. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U and Speed TP. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics (Oxford, England). 2003; 4(2):249-264.
57. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Statistical Applications in Genetics and Molecular Biology. 2004; 3:Article3.
58. Langfelder P and Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC bioinformatics. 2008; 9:559.
59. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2014; URL http://www.R-project.org/.
60. Therneau TM and Grambsch PM. Modeling Survival Data: Extending the Cox Model. Springer, New York. 2000; ISBN 0-387-98784-3.
61. Hothorn T, Hornik K, van de Wiel MA, Zeileis A. Implementing a Class of Permutation Tests: The coin Package. Journal of Statistical Software. 2008; 28(8):1-23.
62. Hu Y and Smyth GK. ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. Journal of immunological methods. 2009; 347(1-2):70-78.
63. Beier D, Schriefer B, Brawanski K, Hau P, Weis J, Schulz JB and Beier CP. Efficacy of clinically relevant temozolomide dosing schemes in glioblastoma cancer stem cell lines. Journal of neuro-oncology. 2012.